Published in Hum Pathol on September 01, 1999
Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol (1999) 1.16
Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol (1999) 1.11
Expression of Epstein-Barr virus in mesopharyngeal and hypopharyngeal carcinomas. Hum Pathol (1999) 1.02
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell (1996) 2.66
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest (2001) 2.20
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol (1987) 2.04
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Expression of ras proto-oncogene proteins in normal human tissues. Oncogene (1987) 1.86
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62
Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am (2006) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Desmoid fibromatosis is a clonal process. Hum Pathol (1996) 1.54
Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst (1994) 1.52
Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res (1994) 1.50
p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci U S A (1999) 1.48
Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem (1994) 1.47
Mzf1 controls cell proliferation and tumorigenesis. Genes Dev (2001) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med (1990) 1.38
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res (1986) 1.36
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst (1998) 1.28
The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.27
Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci U S A (1995) 1.26
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol (1995) 1.26
Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst (1994) 1.26
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24
High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. Cancer Res (1985) 1.24
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol (1994) 1.22
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res (1999) 1.20
Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol (1999) 1.18
Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res (2000) 1.16
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. J Histochem Cytochem (1984) 1.15
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci U S A (1985) 1.14
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res (1999) 1.13
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (1993) 1.13
Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. Am J Pathol (1987) 1.12
Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer (2007) 1.12
Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. J Invest Dermatol (1987) 1.12
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Cancer Res (1997) 1.11
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res (2001) 1.11
Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol (1999) 1.11
Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol (1994) 1.10
Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer (1998) 1.09
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res (2001) 1.09
HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res (2001) 1.09
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res (2001) 1.08
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res (1999) 1.07
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res (2001) 1.07
Allelic deletions in renal tumors: histopathological correlations. Cancer Res (1993) 1.07
Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res (1998) 1.07
Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.06
Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer (2001) 1.06
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res (1995) 1.06
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.05
Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest (2001) 1.05
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol (2000) 1.05